Business context and reporting period
The supplied filing is Celsion Corporation’s Form 10-K for the fiscal year ended December 31, 2019, not a filing under the name Imunon, Inc. Celsion was a clinical-stage oncology company with no product sales. Its lead candidates were ThermoDox, in a Phase III liver-cancer trial, and GEN-1, in clinical development for ovarian cancer.
Key financial metrics
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0.5 million | $0.5 million |
| Research and development expense | $13.1 million | $11.9 million |
| General and administrative expense | $8.0 million | $9.7 million |
| Net loss | $16.9 million | $11.9 million |
| Net cash used in operations | $20.3 million | $7.0 million |
Revenue was licensing-related amortization under the Hisun agreement; the company reported no product revenue. Operating loss was $20.6 million versus $21.1 million. Net loss worsened despite lower operating expenses, principally because the 2018 period included a substantially larger New Jersey tax-benefit gain ($10.4 million versus $1.8 million in 2019). The 2019 results also included a $3.2 million noncash gain from revaluing the EGEN earn-out liability and $1.4 million of interest expense. Product margins are not meaningful because there were no product sales.
At year-end, current assets were $16.2 million, including $14.9 million in cash, cash equivalents, short-term investments and interest receivable; current liabilities were $7.9 million and working capital was $8.3 million, down from $22.0 million in 2018. Total liabilities were $23.7 million. Notes payable were approximately $9.8 million, net of financing costs; the Horizon loan is secured by substantially all company assets other than intellectual property and bears interest at one-month LIBOR plus 7.625%. Operating cash use exceeded reported net loss, and cash and cash equivalents declined to $6.9 million from $13.4 million.
Changes, outlook and material developments
- R&D expense rose 10% year over year, while G&A declined 18%, primarily due to lower noncash stock compensation. The company completed OPTIMA enrollment (556 patients) in August 2018; ongoing costs were lower as the study moved into follow-up.
- For OPTIMA, the first prespecified interim review followed 128 reported deaths. The DMC recommended continuing the trial; the review cited blinded PFS of 17 months and said OS had not yet been reached. The filing says the study remained blinded and does not report an unblinded treatment-effect estimate. A second interim efficacy analysis was expected in Q2 2020 after at least 158 deaths; final analysis, if required, was projected for early 2021.
- GEN-1’s Phase I/II OVATION 2 study was continuing dose escalation. The DSMB recommended continuation after safety review. March 2020 preliminary results reported R0 resections in 7 of 9 GEN-1-treated patients versus 3 of 6 chemotherapy-only patients; these small, early-stage data are not definitive efficacy evidence.
- Management said year-end resources plus $6.4 million raised in early 2020 were expected to fund operations through mid-2021 in several sections. Another passage in the MD&A says through mid-2020; this inconsistency should be clarified. The company also cited roughly $15 million remaining under its JonesTrading equity sales agreement, but had no other committed funding source.
- After year-end, the company completed a registered offering of 4.57 million shares for approximately $4.8 million gross and issued warrants; it also raised funds under the Aspire agreement before terminating it effective March 6, 2020. These financings entail potential dilution. The filing warned that COVID-19 could disrupt trials, enrollment, suppliers and access to capital; the impact was not yet determinable.
- Other notable items: a shareholder derivative/class action concerning approval of the 2018 Stock Incentive Plan was in early stages and its outcome could not be determined; the company reported no further IPR&D impairment in 2019 after a $4.5 million noncash GBM impairment in 2018. Management stated disclosure controls and internal control over financial reporting were effective; the auditor issued an unqualified opinion on the financial statements.
Most important facts to verify
- Confirm entity and period: the supplied document is Celsion Corporation’s 2019 10-K, despite the request naming Imunon, Inc.
- Resolve the conflicting cash-runway statements (mid-2020 versus mid-2021) and assess burn rate against current trial plans.
- Check subsequent cash balances, financing availability, debt service and dilution from shares, warrants, options and equity-sale agreements.
- Review the OPTIMA unblinded interim and final results, statistical plan, event counts and regulatory implications; the filing’s interim discussion is blinded and not proof of efficacy.
- Track OVATION 2 enrollment, safety and randomized Phase II results; distinguish preliminary surgical-response data from confirmatory outcomes.
- Assess the impact of COVID-19 on trial timelines, site activity, supply and financing, along with the status of the shareholder litigation and contingent EGEN earn-out.